ライフサイエンスコーパス: dihydroxyphenylalanine

1 ryloxy radical coupling to form di-DOPA (3,4-dihydroxyphenylalanine).

2 mulating hormone, 8-methoxypsoralen, and 3,4-dihydroxyphenylalanine).

3 ctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine.

4 tyrosine and to a lesser extent against 3,4-dihydroxyphenylalanine.

5 e catalyzes the hydroxylation of tyrosine to dihydroxyphenylalanine.

6 otor deficits that can be rescued with L-3,4 dihydroxyphenylalanine.

7 re not related to melanin formation from 3,4-dihydroxyphenylalanine.

8 alyzes the hydroxylation of tyrosine to form dihydroxyphenylalanine.

9 cts were seen on the binding of dopamine and dihydroxyphenylalanine.

10 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful tool

11 ion, and prognostic value of fused (18)F-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET/MR images in ped

12 on of protein-bound 3-nitrotyrosine and 3, 4-dihydroxyphenylalanine (3-hydroxytyrosine) as specific i

13 for morphine when given either caffeine or l-dihydroxyphenylalanine (a dopamine precursor that restor

14 It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1017,

15 )methyl]chromen-2-one, increased DOPA (L-3,4-dihydroxyphenylalanine) accumulation 51% in the hippocam

16 he incorporation of the amino acid DOPA (3,4-dihydroxyphenylalanine) allows the self-assembled nanofi

17 strated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergic-neu

18 teriovenous increments in plasma levels of L-dihydroxyphenylalanine and dihydroxyphenylglycol did not

19 )H-norepinephrine, and cardiac production of dihydroxyphenylalanine and measurement of left ventricul

20 L-3,4-dihydroxyphenylalanine and reserpine have been used to i

21 scopy have been used to determine that l-3,4-dihydroxyphenylalanine and reserpine increase and decrea

22 alpha-melanocyte-stimulating hormone and 3,4-dihydroxyphenylalanine) and inhibitors (hydroquinone, ar

23 ndance and proximity of catecholic Dopa (3,4-dihydroxyphenylalanine) and lysine residues hint at a sy

24 ecursor and Parkinson's therapy agent, L-3,4-dihydroxyphenylalanine, and at cell clusters incubated w

25 ed natriuresis and diuresis in response to l-dihydroxyphenylalanine, and decreased medullary COX-2 ex

26 ncreased plasma NE, epinephrine (EPI), DHPG, dihydroxyphenylalanine, and DOPAC levels by 4.3, 7.3, 2.

27 Dopamine (DA), its precursor 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxyphen

28 norepinephrine, normal cardiac production of dihydroxyphenylalanine, and normal myocardial 6-[(18)F]f

29 rrioxamine, indicating that cytosolic DA and dihydroxyphenylalanine are oxidized by iron-mediated cat

30 Trp > norleucine > Phe, Leu > Ile > His >3,4-dihydroxyphenylalanine, Arg > Val > Lys, Tyr, Pro > hydr

31 ment with a norepinephrine precursors (l-3,4-dihydroxyphenylalanine at 100 mg/kg or l-threo-dihydroxy

32 t to allow phenylalanine hydroxylase to form dihydroxyphenylalanine at rates comparable to that of ty

33 catalyzes the oxidation of serotonin and 3,4-dihydroxyphenylalanine by H(2)O(2).

34 The specific activities for formation of dihydroxyphenylalanine by the S395A, S395T, and S396A en

35 enic enzymes include Tyrp1 (or TRP1) and 3,4-dihydroxyphenylalanine-chrome tautomerase (Dct or TRP2)

36 The average concentration of di-dihydroxyphenylalanine cross-links in byssal plaques is

37 ed significantly enhanced levels of 5, 5'-di-dihydroxyphenylalanine cross-links.

38 The D stereoisomer of dihydroxyphenylalanine (D-DOPA) and its alpha-keto acid

39 Aspartate 1-decarboxylase (ADC) and 3,4-dihydroxyphenylalanine decarboxylase (DDC) provide beta-

40 a new member of the opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylase gene family (TyDC5)

41 identity with other opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylases (84%), and when ex

42 The high content of 3,4-dihydroxyphenylalanine (Dopa) (~30 mol %) and its locali

43 striatum (ST; 80.3% of F344) and lower basal dihydroxyphenylalanine (DOPA) accumulation after m-hydro

44 a 5-HT(1A) receptor agonist, decreased l-3,4-dihydroxyphenylalanine (DOPA) accumulation in rat striat

45 TH synthesis rate was measured by dihydroxyphenylalanine (DOPA) accumulation in the presen

46 loped for enantiomeric quantification of 3,4-dihydroxyphenylalanine (DOPA) and its precursors, phenyl

47 cuticle of byssal threads given its high 3,4-dihydroxyphenylalanine (Dopa) content at 10-15 mol %.

48 omitantly, GBL treatment [along with the 3,4-dihydroxyphenylalanine (dopa) decarboxylase inhibitor NS

49 ring dopamine synthesis (accumulation of 3,4-dihydroxyphenylalanine (DOPA) following decarboxylase in

50 residue of alpha-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated che

51 etaine) (pCB) and four surface-binding l-3,4-dihydroxyphenylalanine (DOPA) groups, pCB-(DOPA)4, were

52 Dihydroxyphenylalanine (DOPA) histochemistry demonstrate

53 The interaction between a 3,4-dihydroxyphenylalanine (DOPA) labeled analogue of the tr

54 chemically defined minimal medium with L-3,4-dihydroxyphenylalanine (DOPA) or (-)-epinephrine produce

55 3, 4-Dihydroxyphenylalanine (Dopa) residues in Mfps mediate b

56 KM values for substrates, the Vmax value for dihydroxyphenylalanine (DOPA) synthesis, and the couplin

57 d nonenzymatically to the DA precursor l-3,4-dihydroxyphenylalanine (DOPA) under pro-oxidant conditio

58 the cross-linking of proteins containing 3,4-dihydroxyphenylalanine (DOPA) used by shellfish for stic

59 ng sequences in polypeptides to peptidyl 3,4-dihydroxyphenylalanine (DOPA) using mushroom tyrosinase

60 and phenylalanine (PHE) to the synthesis of dihydroxyphenylalanine (DOPA) were studied in PC12 cells

61 exploits the adhesive characteristics of 3,4-dihydroxyphenylalanine (DOPA), an important component of

62 Fava beans (Vicia faba) contain dihydroxyphenylalanine (dopa), and their ingestion may i

63 tive against tyrosine, phenylalanine and 3,4-dihydroxyphenylalanine (dopa), tdc1 was developmentally

64 pectinata foot protein-1, apfp-1) with L-3,4-dihydroxyphenylalanine (DOPA)-containing and mannose-bin

65 As the first of the 3,4-dihydroxyphenylalanine (Dopa)-containing byssal precurso

66 We found that only l-3,4-dihydroxyphenylalanine (DOPA)-containing peptides were s

67 We previously reported l-3,4-dihydroxyphenylalanine (dopa)-histidine (dopa-His) as an

68 le animal models of PD fail to display l-3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonism an

69 xpressed by the selective recognition of 3,4-dihydroxyphenylalanine (DOPA).

70 that catalyzes the conversion of tyrosine to dihydroxyphenylalanine (DOPA).

71 trans-2,3-cis-3,4-dihydroxyproline, and 3,4-dihydroxyphenylalanine (Dopa).

72 transferase (PST), SULT1A3, has a unique 3,4-dihydroxyphenylalanine (Dopa)/tyrosine-sulfating activit

73 the pancreas itself has a high dopamine [and dihydroxyphenylalanine (dopa)] content that does not cha

74 ls of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HV

75 mines significant to the fly including L-3,4-dihydroxyphenylalanine, dopamine, tyramine, and serotoni

76 This was achieved using [(18)F]fluoro-levo-dihydroxyphenylalanine dynamic positron emission tomogra

77 iorally effective dose of DA precursor l-3,4-dihydroxyphenylalanine effectively reversed these change

78 hesis capacity was measured by fluorine-18-l-dihydroxyphenylalanine (F-18-FDOPA) positron emission to

79 of phenylalanine hydroxylase is critical for dihydroxyphenylalanine formation.

80 s can be trapped by added catechol or by the dihydroxyphenylalanine formed during turnover.

81 ly relevant cargos, nipecotic acid and l-3,4-dihydroxyphenylalanine (i.e., l-DOPA), were attached to

82 to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine in catecholamine biosynthesis.

83 es the hydroxylation of tyrosine to form 3,4-dihydroxyphenylalanine in the biosynthesis of the catech

84 Dopa (3,4-dihydroxyphenylalanine) is recognized as a key chemical

85 resents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial octa

86 han, R(**) is dihydroxyarginine, Y(*) is 3,4-dihydroxyphenylalanine, K(*) is 5-hydroxylysine, and K(*

87 nt 1 established that DD mice treated with L-dihydroxyphenylalanine (L-dopa [LD]) perform similarly t

88 ty in dopamine-deficient mice than did l-3,4-dihydroxyphenylalanine (l-dopa) administration, which pa

89 exaggerated rotational behavior induced by L-dihydroxyphenylalanine (L-DOPA) and contralateral sensor

90 ibe a simple one-pot method, employing l-3,4-dihydroxyphenylalanine (L-DOPA) as a reducing/capping re

91 ynthesized by hydroxylation of tyrosine to L-dihydroxyphenylalanine (L-Dopa) by tyrosine hydroxylase

92 eatment of Parkinson disease (PD) with L-3,4-dihydroxyphenylalanine (L-DOPA) dramatically relieves as

93 -) mice required daily administration of 3,4-dihydroxyphenylalanine (L-DOPA) for survival beyond 2 to

94 The application of L-3,4-dihydroxyphenylalanine (L-DOPA) increased the IPSC in Le

95 The dopamine precursor L-beta-3,4-dihydroxyphenylalanine (L-DOPA) inhibited cleavage of 35

96 The catecholamine precursor l-dihydroxyphenylalanine (L-DOPA) is the primary therapeut

97 aline; a synthetic dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA) methyl ester; a direct d

98 SKF 82958 and the indirect DA agonist L-3,4-dihydroxyphenylalanine (L-DOPA) on the acoustic startle

99 tested in 7 aged rhesus monkeys using L-3,4-dihydroxyphenylalanine (L-dopa) or the selective dopamin

100 Although L-3,4-dihydroxyphenylalanine (L-DOPA) remains the reference tr

101 oss of midbrain dopaminergic neurons and 3,4-dihydroxyphenylalanine (L-DOPA) reversible behavioral de

102 of dyskinesia that result from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) therapy.

103 Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores bra

104 opamine D1 or D2 receptor agonists and l-3,4-dihydroxyphenylalanine (l-DOPA) was 3- to 13-fold greate

105 g" clinical practice that avoids using L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precursor, i

106 be achieved by daily administration of L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopamine

107 lar oxygen to hydroxylate tyrosine to form L-dihydroxyphenylalanine (L-DOPA), and tetrahydrobiopterin

108 eated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (L-DOPA), but its prolonged use c

109 ng freely, and injected with 100 mg/kg l-3,4-dihydroxyphenylalanine (L-DOPA), engage in a behavior (a

110 istration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by activ

111 ignificantly less amounts of dopamine, l-3,4-dihydroxyphenylalanine (L-DOPA), salsolinol, and N-acety

112 Furthermore, in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

113 isrupted in Parkinson's disease and in l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID)

114 as a structure putatively involved in L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesia (LID)

115 gonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

116 loped treatment complications known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

117 of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID)

118 L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia is an

119 incubated with the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA).

120 s after exposure to the dopamine precursor L-dihydroxyphenylalanine (L-DOPA).

121 ine receptor agonists apomorphine and L-3, 4-dihydroxyphenylalanine (L-DOPA).

122 he 3-hydroxylation of tyrosine to form l-3,4-dihydroxyphenylalanine (l-DOPA).

123 be maintained by daily treatment with l-3,4-dihydroxyphenylalanine (L-dopa).

124 be synthesized by another pathway via l-3,4-dihydroxyphenylalanine (L-DOPA).

125 ne is restored by daily treatment with l-3-4-dihydroxyphenylalanine (l-dopa).

126 nless the animals were pretreated with l-3,4-dihydroxyphenylalanine (l-dopa).

127 inistration of the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-dopa).

128 by administration of the tyrosinase product dihydroxyphenylalanine (l-dopa).

129 ey are rescued by daily treatment with L-3,4-dihydroxyphenylalanine (L-DOPA); each dose restores dopa

130 l dopamine (DA) replacement with Levodopa [L-dihydroxyphenylalanine (L-DOPA)] is the gold standard tr

131 l-3,4-dihydroxyphenylalanine-mediated dyskinesias were also si

132 Dopamine- and 3,4-dihydroxyphenylalanine-melanin products were identified

133 Ultraviolet-Vis absorbance spectra of L-3,4-dihydroxyphenylalanine-melanin solutions at different co

134 Analytes including L-3,4-dihydroxyphenylalanine, N-acetyl octopamine, N-acetyldop

135 ed after treatment with the catecholamines L-dihydroxyphenylalanine, norepinephrine, epinephrine, and

136 ion remains largely limited to the Dopa (3,4-dihydroxyphenylalanine) or catechol functionality, which

137 g using the dopamine precursor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonists re

138 gic analysis using hematoxylin and eosin and dihydroxyphenylalanine oxidase special stains.

139 osine hydroxylase activity of tyrosinase and dihydroxyphenylalanine oxidation drop rapidly, while DOP

140 ibited occasional large complexes containing dihydroxyphenylalanine-positive cisterna and 50 nm vesic

141 f HPS1 protein resulted in the deposition of dihydroxyphenylalanine reaction products (i.e., tyrosina

142 n cultured human RPE, KL increases the l-3,4-dihydroxyphenylalanine synthesis and inhibits vascular e

143 o[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippocampus

144 (spillovers) and regional plasma levels of L-dihydroxyphenylalanine (the immediate product of the rat

145 In the case of binding of dihydroxyphenylalanine, the decrease in affinity upon ph

146 L-3,4-dihydroxyphenylalanine, the immediate precursor of dopam

147 behaviors (dyskinesias) in response to l-3,4-dihydroxyphenylalanine, the principal treatment for Park

148 th Parkinson's disease receiving long-term l-dihydroxyphenylalanine therapy, the results of the prese

149 ine, norepinephrine, octopamine (OA), L-3, 4-dihydroxyphenylalanine, tyramine (TA), and serotonin as

150 igra and PC12 cell cultures by exposure to l-dihydroxyphenylalanine, which is rapidly converted to do